Bachem stock trades 0.47 percent above its EUR 85.45 prior close

Published on 10/05/2026 at 15:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bachem sales rose 4.00 percent to CHF 326.40 million in the first half of 2026. Bachem stock stands at EUR 85.85 on October 5, 2026 versus EUR 85.45.

Fotorealistische Peptid-Produktionsanlage mit Alpenpanorama im Hintergrund — Bachem Holding AG (CH0012530207) betreibt moderne Peptid-Produktionsanlagen mit Bioreaktoren vor Schweizer Alpenpanorama, Illustration mit AI erstellt.

Bachem stock was trading at EUR 85.85 at Lang & Schwarz on October 5, 2026, up 0.47 percent versus the prior close of EUR 85.45. In the first half of 2026, sales rose 4.00 percent year over year to CHF 326.40 million, according to the Yahoo Finance transcript dated July 30, 2026.

Sales growth meets a tougher margin

Bachem's reported EBITDA margin was 25.40 percent in the first half of 2026, down 3.70 percentage points from the prior-year period. Management attributed the pressure to costs supporting future growth, including additional staff, maintenance and capacity investments.

That trade-off is visible in the investment figures. Bachem invested CHF 148.00 million in capacity during the first six months of 2026, while operating cash flow reached CHF 104.70 million, according to Yahoo Finance.

Guidance narrows on production visibility

For full-year 2026, Bachem expects sales growth of 35.00-40.00 percent in local currencies, compared with its earlier range of 35.00-45.00 percent. The company kept its profitability outlook at an EBITDA margin in the low 30 percent range.

The narrower sales range reflects greater visibility into the detailed production schedule for the second half of 2026, rather than a stated change to the underlying growth strategy. Building K is expected to contribute sales in the second half, while Bachem said orders for the remainder of 2026 were already in its books, according to Yahoo Finance.

Capacity remains the central valuation issue

Bachem plans 2026 capital expenditure of CHF 350.00 million to CHF 400.00 million and is advancing the Sisslerfeld site with an investment of more than CHF 500.00 million. Commercial production at the site is expected in 2030, making execution and financing important factors for the medium-term growth case.

The company develops and manufactures peptides and oligonucleotides for pharmaceutical and biotechnology customers. Its shares trade on SIX under ticker BANB and ISIN CH1176493729, as listed by Global Banking and Finance.

Stock stays below its September high

On SIX SX, Bachem stock stood at CHF 79.85 at 12:28 p.m. CEST on October 5, 2026. The session high was CHF 80.30, while the 52-week high of CHF 84.10 was reached on September 23, 2026. At Lang & Schwarz, the euro quote was EUR 85.85 at 3:04 p.m. CEST on October 5, 2026, versus a prior close of EUR 85.45 and a daily gain of 0.47 percent. The further course of trading is shown by the continuously updated real-time quote of Bachem stock.